onr:"swepub:oai:gup.ub.gu.se/54327"
Sökning: onr:"swepub:oai:gup.ub.gu.se/54327" > Long-term treatment...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 03178naa a2200313 4500 | |
| 001 | oai:gup.ub.gu.se/54327 | |
| 003 | SwePub | |
| 008 | 240528s2007 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://gup.ub.gu.se/publication/543272 URI |
| 024 | 7 | a https://doi.org/10.1080/028418606010160622 DOI |
| 040 | a (SwePub)gu | |
| 041 | a eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Taheri-Kadkhoda, Zahra,d 1969u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences4 aut0 (Swepub:gu)xtahza |
| 245 | 1 0 | a Long-term treatment results for nasopharyngeal carcinoma: the Sahlgrenska University Hospital experience. |
| 264 | c 2009-07-08 | |
| 264 | 1 | b Informa UK Limited,c 2007 |
| 520 | a Nasopharyngeal carcinoma (NPC) is a rare disease in Sweden. For evaluation of the treatment outcomes in our NPC patients, 52 new cases that were referred to our department between 1991 and 2002 were retrospectively analysed. Tumor stage, according to the 1997 AJCC staging system, was I in five, II in ten, III in 12 and IV in 25 patients. Majority of the patients (87%) had World Health Organization type II-III tumors. Neoadjuvant chemotherapy was delivered in 33 patients. Thirty-two patients received hyperfractionated accelerated radiation therapy with a median dose of 64.6Gy (1.7Gy/fr bid). Conventional external irradiation with a median dose of 66Gy (2Gy/fr) was delivered to 18 patients. An intracavitary brachy-boost of 4.5-12Gy was delivered to 40 patients. Two patients were excluded from the analysis due to treatment refusal. For the patients with tumor stages I-IVB, the 5-year disease-free and overall survival rates were 61% and 55%, respectively. The 5-year local, regional, and distant relapse-free survival rates were 70%, 92% and 77%, respectively. The most frequent late side effects were xerostomia (98%), otitis (70%) and hearing deterioration (64%). Our data suggest that optimization of the treatment outcomes in NPC patients requires implementation of new therapeutic strategies. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
| 700 | 1 | a Björk-Eriksson, Thomas,d 1960u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences4 aut0 (Swepub:gu)xbjoth |
| 700 | 1 | a Johansson, Karl-Axelu Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences4 aut |
| 700 | 1 | a Mercke, Claes,d 1941u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences4 aut0 (Swepub:gu)xmercl |
| 710 | 2 | a Göteborgs universitetb Institutionen för kliniska vetenskaper4 org |
| 773 | 0 | t Acta oncologica (Stockholm, Sweden)d : Informa UK Limitedg 46:6, s. 817-27q 46:6<817-27x 0284-186Xx 1651-226X |
| 856 | 4 8 | u https://gup.ub.gu.se/publication/54327 |
| 856 | 4 8 | u https://doi.org/10.1080/02841860601016062 |
Hitta via bibliotek
- Acta oncologica (Stockholm, Sweden) (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Taheri-Kadkhoda, ...
- Björk-Eriksson, ...
- Johansson, Karl- ...
- Mercke, Claes, 1 ...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Cancer och onkol ...
- Artiklar i publikationen
- Acta oncologica ...
- Av lärosätet
- Göteborgs universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
